Industry News

• Pivotal Phase 3 study compares tapentadol extended release tablets to placebo  Phase 3 safety and efficacy data comparing tapentadol extended release (ER) tablets, an investigational pain medication, to placebo in patients with moderate to severe chronic osteoarthritis knee pain have been published by Clinical Drug Investigation.
  Johnson & Johnson August 30, 2010  
• NIH Loan Repayment Programs relieve researchers' educational debt   As medical education costs rise, NIH Loan Repayment Programs have, for nearly 10 years, supported early stage investigators by repaying up to $35,000 of educational debt annually for investigators who commit to at least two years of research funded by a U.S. nonprofit, university or government body.
  National Institutes of Health August 30, 2010  
• Albemarle names Karen G. Narwold Senior Vice President and General Counsel  Albemarle Corporation announced that Karen G. Narwold has joined the company as Senior Vice President and General Counsel. Ms. Narwold will assume responsibility for all legal matters related to the corporation on September 13, 2010.
  Albemarle Corporation August 30, 2010  
• Viruses found in chronic fatigue syndrome patients  New research supports the idea that viruses may play a role in chronic fatigue syndrome (CFS), a debilitating disease that affects millions of people nationwide.
  National Institutes of Health August 30, 2010  
• Albemarle increases prices of FCC catalysts and implements rare earth surcharges  Albemarle will increase prices of FCC catalysts by 10% globally, effective October 1, 2010, or as contracts allow. In addition, Albemarle will implement rare earth surcharges on FCC catalysts and additives, effective October 1, 2010.
  Albemarle Corporation August 30, 2010  
• BARDA funds $27 million drug development for biothreats, antibiotic resistance to Achaogen  HHS has awarded a contract to develop an antibiotic that could be used against possible two types of bioterrorism and common infections becoming resistant to antibiotics. The contract to Achaogen of San Francisco is for $27 million in the first two years, and can be extended for three years.
  U.S. Dept of Health & Human Services August 30, 2010  
• 3M to acquire Cogent Inc. for $943 million  3M and Cogent announced an agreement for 3M’s acquisition of Cogent Inc. for $10.50 per share with an aggregate value of approximately $943 million. Cogent provides finger, palm, face and iris biometric systems for governments, law enforcement agencies, and commercial enterprises.
  3M Company August 30, 2010  
• Genzyme confirms receipt of unsolicited Sanofi-Aventis proposal  Genzyme confirmed that it has received an unsolicited, non-binding proposal from Sanofi-Aventis to acquire all the outstanding shares of Genzyme for $69 per share in cash. The Genzyme board of directors met last night, unanimously affirmed its previous rejection of Sanofi’s proposal.
  Genzyme Corp. August 30, 2010  
• Idera Pharmaceuticals achieves clinical milestone under its collaboration with Merck  Idera announced a milestone under its agreement with Merck achieved upon Merck's initiation of a Phase 1b clinical trial of IMO-2055, an agonist of Toll-like Receptor 9, in combination with cisplatin, fluorouracil and cetuximab in first-line treatment of patients with squamous cell carcinoma.
  Idera Pharmaceuticals, Inc. August 27, 2010  
• Charles River implements $300 million accelerated stock repurchase program  Charles River Laboratories announced that it has implemented an accelerated stock repurchase program to repurchase $300 million of common stock, as part of its previously announced authorization from its Board of Directors to repurchase up to $500 million of common stock.
  Charles River Laboratories International August 27, 2010  

(previous 10 articles)    (next 10 articles)